Loncastuximab tesirine

Generic Name
Loncastuximab tesirine
Brand Names
Zynlonta
Drug Type
Biotech
Chemical Formula
-
CAS Number
1879918-31-6
Unique Ingredient Identifier
7K5O7P6QIU
Background

Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...

Indication

Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under...

Associated Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed Diffuse large B-cell lymphoma NOS, Relapsed High Grade B-cell Lymphoma (HGBCL)
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath